ACAD stock forecast
Our latest prediction for ACADIA Pharmaceuticals, Inc.'s stock price was made on the Sept. 20, 2019 when the stock price was at 40.74$.
In the short term (2weeks), ACAD's stock price should outperform the market by 3.18%. During that period the price should oscillate between -9.68% and +12.76%.
In the medium term (3months), ACAD's stock price should outperform the market by 2.98%. During that period the price should oscillate between -20.24% and +31.02%.Get email alerts
Create a solid portfolio with ACAD
About ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
At the moment the company generates 264M USD in revenues.
On its last earning announcement, the company reported a loss of -1.97$ per share.
The book value per share is 2.12$
Three months stock forecastSept. 20, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|